XBIO · Xenetic Biosciences, Inc.
$3.59
+0.20 (+5.90%)
At close · Aug 21
Market Cap
$8.41M
Shares
2.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.98M
+19%
FY2025
Net Income
-$2.68M
+32.3%
FY2025
Gross Margin
100%
+15.3pp
FY2013
Operating Margin
-95.23%
+72.9pp
FY2025
Diluted EPS
-$1.58
+38.5%
FY2025
Operating Cash Flow
-$2.29M
+18.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.26M | $2.98M | $2.5M | $2.54M | $1.71M | $1.16M | $436.94K | $17.07K | $0 | $7.59M | $3M | $0 | $0 | $1M | $293.6K | |
| — | $148K | $249.86K | $355.76K | $167.15K | $100.47K | $126.17K | $108.49K | $509 | -$1818 | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $44.84K | |
| — | — | — | — | — | — | — | — | — | — | — | — | $0 | $1M | $248.77K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | 100% | 84.73% | |
| $2.74M | $3.07M | $3.29M | $3.49M | $4.77M | $3.16M | $1.73M | $4.89M | $2.88M | $4.06M | $43.74M | $3.43M | $6.32M | $3.06M | $1.94M | |
| $3.16M | $2.75M | $3.42M | $3.56M | $3.65M | $3.74M | $3.4M | $4.73M | $4.39M | $6.94M | $6.69M | $6.39M | $6.6M | $6.55M | $3.56M | |
| — | — | — | — | $0 | $0 | $1000 | — | — | — | — | $56.12K | $88.69K | $52.03K | — | |
| $5.9M | $5.81M | $6.7M | $7.06M | $8.42M | $6.91M | $14.37M | $12.9M | $7.28M | — | — | — | $12.92M | $9.61M | $6.59M | |
| -$2.64M | -$2.83M | -$4.2M | -$4.52M | -$6.72M | -$5.75M | -$13.94M | -$12.89M | -$7.28M | -$3.57M | -$47.43M | -$9.82M | -$12.92M | -$8.61M | -$6.34M | |
| — | -95.23% | -168.16% | -177.79% | -393.57% | -495.12% | -3189.82% | -75511.71% | — | -47.05% | -1581.02% | — | — | -861.35% | -2160.83% | |
| — | — | — | — | -$6.72M | -$5.75M | -$13.94M | — | — | — | — | -$9.77M | -$12.84M | -$8.56M | — | |
| — | — | — | — | — | — | — | — | — | $1818 | $729.57K | $267K | $4706 | $632 | $51.74K | |
| — | — | — | — | — | — | — | — | — | — | — | — | $18.96K | $34.86K | $67.67K | |
| $166.48K | $153.72K | $244.15K | $381.14K | $165.56K | $101.59K | $125.68K | $111.8K | -$24.13K | -$26.37K | -$6.78M | -$2.69M | -$1.38M | -$31.95K | $15.94K | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$14.31M | -$8.58M | -$6.33M | |
| $0 | $0 | $0 | $0 | $0 | $0 | -$2.92M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$2.48M | -$2.68M | -$3.96M | -$4.13M | -$6.55M | -$5.65M | -$10.89M | -$12.78M | -$7.3M | -$3.6M | -$54.21M | -$12.51M | -$14.31M | -$8.58M | -$6.33M | |
| — | -90.07% | -158.39% | -162.78% | -383.87% | -486.36% | -2493.11% | -74856.59% | — | -47.4% | -1806.87% | — | — | -857.92% | -2155.41% | |
| — | — | — | — | — | — | -$10.89M | -$18.06M | -$7.3M | -$3.6M | -$58.24M | -$12.51M | — | — | — | |
| — | — | — | — | — | — | — | — | — | -$3.6M | -$54.21M | -$12.83M | -$14.63M | -$8.59M | -$5.16M | |
| USD/shares | — | -$1.58 | -$2.57 | -$2.71 | -$4.61 | -$5.50 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.58 | -$2.57 | -$2.71 | -$4.61 | -$5.50 | — | — | — | — | — | — | — | — | — |
| shares | — | 1.7M | 1.54M | 1.53M | 1.42M | 1.03M | 639.24K | 285.25K | 75.6K | 866.58K | 743.06K | 422.39K | 13.59M | 11.98M | 11.98M |
| shares | — | 1.7M | 1.54M | 1.53M | 1.42M | 1.03M | 639.24K | 285.25K | 75.6K | 866.58K | 743.06K | 422.39K | 13.59M | 11.98M | 11.98M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.66×
EV/EBIT
—
Peer median 11.20×
P/E (TTM)
—
Peer median 3.14×
Peer medians compare against the 194 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| Royalty | $1,160,692 | $436,942 |